{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:27:21Z","timestamp":1786994841846,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.neurobiolaging.2017.12.018","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T03:09:38Z","timestamp":1514344178000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Amyloid pathology in the progression to mild cognitive impairment"],"prefix":"10.1016","volume":"64","author":[{"given":"Philip S.","family":"Insel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Mackin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/archpsyc.57.11.1071","article-title":"Cerebral white matter lesions and depressive symptoms in elderly adults","volume":"57","author":"de Groot","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib3","doi-asserted-by":"crossref","first-page":"8237","DOI":"10.1523\/JNEUROSCI.5506-12.2013","article-title":"Brain changes in older adults at very low risk for Alzheimer's disease","volume":"33","author":"Fjell","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"Pt 8","key":"10.1016\/j.neurobiolaging.2017.12.018_bib5","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/aww139","article-title":"The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging","volume":"139","author":"Gordon","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib6","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib7","series-title":"Generalized Additive Models","author":"Hastie","year":"1990"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acn3.192","article-title":"Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease","volume":"2","author":"Insel","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib9","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1212\/WNL.0000000000002683","article-title":"Accelerating rates of cognitive decline and imaging markers associated with \u03b2-amyloid pathology","volume":"86","author":"Insel","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jmri.21049","article-title":"The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods","volume":"27","author":"Jack","year":"2008","journal-title":"J.\u00a0Magn. Reson. Imaging"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/jnp.12.2.233","article-title":"Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory","volume":"12","author":"Kaufer","year":"2000","journal-title":"J.\u00a0Neuropsychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","article-title":"Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease","volume":"78","author":"Knopman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1037\/0894-4105.21.4.412","article-title":"Longitudinal MRI and cognitive change in healthy elderly","volume":"21","author":"Kramer","year":"2007","journal-title":"Neuropsychology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.23650","article-title":"Amyloid deposition, hypometabolism, and longitudinal cognitive decline","volume":"72","author":"Landau","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","article-title":"CSF tau\/Amyloid-beta 42 ratio for increased risk of mild cognitive impairment: A follow-up study","volume":"69","author":"Li","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer's disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acn3.81","article-title":"Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease","volume":"1","author":"Mattsson","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib20","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.15252\/emmm.201707809","article-title":"18F-AV- 1451 CSF T-tau P-tau as biomarkers Alzheimer's disease","volume":"9","author":"Mattsson","year":"2017","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib21","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1212\/01.wnl.0000224698.67660.45","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"66","author":"Mckeith","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib22","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/NEN.0b013e3181919a48","article-title":"Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship","volume":"68","author":"Nelson","year":"2017","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","article-title":"Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology","volume":"51","author":"Olsson","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/WNL.0b013e3181c0665f","article-title":"Predicting the time of conversion to MCI in the elderly","volume":"73","author":"Oulhaj","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat. Commun"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib27","first-page":"1","article-title":"Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community","volume":"55905","author":"Petersen","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J.\u00a0Gerontol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the Trail Making Test as an indicator of organic brain damage","volume":"8","author":"Reitan","year":"1958","journal-title":"Percept. Mot. Skills"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib30","series-title":"L'examen clinique en psychologie., Lexamen clinique en psychologie","author":"Rey","year":"1958"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib31","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A\u00a0new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jagp.2015.03.006","article-title":"Chronic depressive symptomatology in mild cognitive impairment is associated with frontal atrophy rate which hastens conversion to Alzheimer dementia","volume":"24","author":"Sacuiu","year":"2016","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib33","first-page":"239","article-title":"Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without flair","volume":"21","author":"Schwarz","year":"2009","journal-title":"Inf. Process. Med. Imaging"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jalz.2014.10.008","article-title":"Vascular contributions to cognitive impairment and dementia including Alzheimer's disease","volume":"11","author":"Snyder","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/WNL.0b013e3181af79e5","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib38","series-title":"Manual for Wechsler Memory Scale - Revised","author":"Wechsler","year":"1987"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/brain\/awl388","article-title":"Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease","volume":"130","author":"Whitwell","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib40","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0028-3932(89)90186-3","article-title":"Boston naming test in Alzheimer's disease","volume":"27","author":"Williams","year":"1989","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neurobiolaging.2017.12.018_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1983","journal-title":"J.\u00a0Psychiatr. Res."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745801730413X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019745801730413X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:27:02Z","timestamp":1759318022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019745801730413X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":42,"alternative-id":["S019745801730413X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.12.018","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloid pathology in the progression to mild cognitive impairment","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}